Cookies?
Library Header Image
LSE Research Online LSE Library Services

Does NICE influence the adoption and uptake of generics in the UK?

Serra-Sastre, Victoria, Bianchi, Simona, Mestre-Ferrandiz, Jorge and O’Neill, Phill (2021) Does NICE influence the adoption and uptake of generics in the UK? European Journal of Health Economics, 22 (2). 229 - 242. ISSN 1618-7598

[img] Text (Serra-Sastre2021_Article_DoesNICEInfluenceTheAdoptionAn) - Published Version
Available under License Creative Commons Attribution.

Download (1MB)
Identification Number: 10.1007/s10198-020-01245-1

Abstract

The aim of this paper is to examine generic competition in the UK, with a special focus on the role of Health Technology Assessment (HTA) on generic market entry and diffusion. In the UK, where no direct price regulation on pharmaceuticals exists, HTA has a leading role for recommending the use of medicines providing a non-regulatory aspect that may influence the dynamics in the generic market. The paper focuses on the role of Technology Appraisals issued by the National Institute for Health and Care Excellence (NICE). We follow a two-step approach. First, we examine the probability of generic entry. Second, conditional on generic entry, we examine the determinants of generic market share. We use data from IQVIA British Pharmaceutical Index (BPI) for the primary care market for 60 products that lost patent between 2003 and 2012. Our results suggest that market size remains one of the main drivers of generic entry. After controlling for market size, intermolecular substitution and difficulty of manufacturing increase the likelihood of generic entry. After generic entry, our estimates suggest that generic market share is highly state dependent. Our findings also suggest that while NICE recommendations do influence generic uptake, there is only marginal evidence they affect generic entry.

Item Type: Article
Official URL: https://www.springer.com/journal/10198
Additional Information: © 2020 The Authors
Divisions: Health Policy
Subjects: R Medicine > RA Public aspects of medicine
R Medicine > RM Therapeutics. Pharmacology
JEL classification: I - Health, Education, and Welfare > I1 - Health > I11 - Analysis of Health Care Markets
I - Health, Education, and Welfare > I1 - Health > I18 - Government Policy; Regulation; Public Health
Date Deposited: 04 Feb 2022 17:27
Last Modified: 10 Feb 2022 10:27
URI: http://eprints.lse.ac.uk/id/eprint/113639

Actions (login required)

View Item View Item

Downloads

Downloads per month over past year

View more statistics